Close menu




Biotech

Photo credits: pixabay.com

Commented by Stefan Feulner on January 14th, 2025 | 07:55 CET

Qiagen, Vidac Pharma, and Bayer with groundbreaking news

  • Pharma
  • Biotechnology
  • Biotech

In the years to come, biotechnology will play a central role in solving global challenges. From the development of innovative therapies to sustainable agriculture and biobased industries, biotechnology combines science and technology to make the world more sustainable and efficient. As a driver of growth and innovation, it offers enormous opportunities for companies and investors who want to actively shape the future.

Read

Commented by André Will-Laudien on January 6th, 2025 | 07:00 CET

Biotech-Rally 2025: Evotec, BioNTech, Vidac Pharma, Pfizer and Bayer are on the buy list

  • Biotechnology
  • Pharma
  • Biotech

For two years, there was almost no movement in the biotech sector. Not even the trend of falling interest rates that began in 2024 could persuade investors to make larger investments. Meanwhile, AI and high-tech stocks continued to perform well, driving the Nasdaq 100 index up by over 30%. However, in the last quarter of 2024, some bombed-out life sciences stocks saw significant markups, and new takeover rumours also began circulating. Whether the sentiment can continue to rise in the coming weeks is something we will explore further. Let's take a closer look at our top picks for 2025.

Read

Commented by Armin Schulz on December 27th, 2024 | 07:10 CET

Volkswagen, Globex Mining, Novo Nordisk – Here are the opportunities for the coming year

  • Mining
  • Gold
  • Commodities
  • Electromobility
  • Biotechnology

The vbw commodity price index recorded a remarkable increase of 4.4% in October 2024 compared to the previous month – an increase of 18.4% year-on-year. On the one hand, this is surprising, as the economy has reportedly noticeably slowed down. On the other hand, geopolitical tensions seem to be causing overcompensation. Raw materials are the engine of the economy, and it is not for nothing that the price of copper is considered a leading indicator of economic activity. In times of export restrictions, it is clear how dependent the world is on China and Russia. Without the crucial raw materials, production comes to a halt. We take a look at three companies and assess whether they are well-positioned in the raw materials sector for the upcoming year.

Read

Commented by Juliane Zielonka on December 23rd, 2024 | 11:55 CET

Pharma stocks in focus: Setback for Novo Nordisk, spot-on performance for Vidac Pharma and Bayer

  • Biotechnology
  • Biotech
  • Pharma

Updates from the pharmaceutical and biotech sector for investors: The Danish company Novo Nordisk is experiencing a setback in the development of its new weight loss drug, CagriSema. Vidac Pharma and Bayer, on the other hand, have positive news to report. The biotech company has received an extension of patent protection for its innovative cancer drugs from the US Patent Office, presenting a unique opportunity for investors. Bayer is also celebrating a success: the higher-dose version of the eye drug Eylea has delivered convincing results in the latest study. This means that in the future, patients will require less frequent injections into the eye. We take a closer look at the developments.

Read

Commented by Fabian Lorenz on December 23rd, 2024 | 08:05 CET

Takeover candidates 2025: Plug Power, Evotec, Desert Gold

  • Mining
  • Gold
  • Biotechnology
  • Hydrogen
  • Fuelcells

Will Plug Power be taken over, or is there a risk of a sharp drop in the share price? The latter is possible in the coming weeks, and shareholders must be careful. A hot takeover candidate in the gold sector is Desert Gold. Analysts see significant upside potential, and the Company is convincing with an exciting mix: production is expected to start in 2025, the resource has increased to 2 million ounces, and gold producers with deep pockets are active in the neighbourhood. At Evotec, a takeover attempt – albeit an amateurish one – has already failed this year. Will financial investor Triton make a serious bid in 2025, or will Deutsche Bank prove right with a target price of EUR 4?

Read

Commented by Fabian Lorenz on December 19th, 2024 | 07:00 CET

Evotec, Rheinmetall, Vidac Pharma: Buy recommendation, cancer revolution, or price collapse?

  • Biotechnology
  • Biotech
  • Defense

Analysts see significant potential for multiplication with Vidac Pharma's stock. It has already been one of the standout performers in the biotech sector in the second half of the year. The Company aims to revolutionize cancer treatment and has published the next top news. Analysts also see further price potential for Rheinmetall. However, shareholders should brace themselves for a possible significant correction in the share price of Germany's largest defense contractor. By contrast, opinions on Evotec remain divided. Is the share price at risk of halving again after a year to forget? Or is now the time to buy in?

Read

Commented by Juliane Zielonka on December 13th, 2024 | 07:00 CET

Medical milestones from Novo Nordisk, BioNxt and Bayer: New hope for millions of patients

  • Biotechnology
  • Biotech
  • Pharma

Medical research is currently making remarkable progress in the treatment of serious diseases. Three companies in this field are reporting important developments that could improve the lives of many people: the Danish pharmaceutical company Novo Nordisk is consolidating its leading position in the fight against obesity with a market share of over 30% in GLP-1 drugs and is driving global expansion. At the same time, the Canadian company BioNxt Solutions is developing a groundbreaking MS therapy: an innovative and simple administration could significantly ease the daily medication routine for MS patients. Bayer, in turn, is starting an important study for a novel cancer drug that is expected to be particularly effective against aggressive tumour types due to its unique mechanism of action. The specific benefits offered by the new therapies and how they change patients' lives are factors that investors should consider when making their next investment decisions.

Read

Commented by Stefan Feulner on December 10th, 2024 | 07:30 CET

Novo Nordisk, BioNxt Solutions, Bayer – The market continues to boom

  • Biotechnology
  • Biotech
  • Pharma

The weight-loss drug market was one of the fastest-growing sectors in the past year and shows no signs of slowing down in 2025. Companies like Novo Nordisk have seen their valuations multiply in recent years, significantly boosting their market capitalization. At the same time, smaller life sciences companies in the second tier, such as those with breakthrough technologies, offer interesting entry opportunities.

Read

Commented by André Will-Laudien on December 10th, 2024 | 07:00 CET

Biotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer

  • Biotech
  • Pharma
  • Biotechnology

There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector.

Read

Commented by Armin Schulz on December 5th, 2024 | 07:15 CET

Evotec has exploded – Will BioNxt Solutions and Bayer follow suit?

  • Biotechnology
  • Biotech
  • Pharma

The biotechnology and pharmaceutical industries are among the most advanced and forward-looking sectors of the global economy. With the development of innovative drugs, therapies, and technologies, the industry is pursuing the goal of sustainably improving the quality of life of millions of people. Intensive research, enormous investments, and a strong focus on groundbreaking innovations define this field, where science and technology work together in close cooperation. Companies such as Evotec, Bayer, and BioNxt Solutions are among the most interesting players in Germany. We take a look at the latest developments.

Read